Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product
Status:
Recruiting
Trial end date:
2022-02-17
Target enrollment:
Participant gender:
Summary
This study will investigate the bioavailability in fasting male and/or non-pregnant and non-
breast feeding female subjects of 1 tablet formulation containing Levodopa 250 mg and
Carbidopa 25 mg. The study will be performed at a single site with 44 subjects. Participants
will take 1 tablet of the test product and reference product in 2 periods and 2 sequences
(either test after reference or reference after test). There will be a washout of at least 2
days between each study period.